Видео ютуба по тегу Keynote-B61

KEYNOTE-B61: Extended Follow-Up Analysis
KEYNOTE-B61: Extended Follow-Up Analysis
KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC
KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC
KEYNOTE-B61: Putting a Focus on Non-Clear Cell RCC Treatment
KEYNOTE-B61: Putting a Focus on Non-Clear Cell RCC Treatment
Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC
Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC
KEYNOTE-B61 Study Results and a Focus on Non-Clear Cell Kidney Cancer
KEYNOTE-B61 Study Results and a Focus on Non-Clear Cell Kidney Cancer
Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale
Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale
KEYNOTE-775: Ленватиниб + Пембролизумаб в лечении распространённого эндометриального рака
KEYNOTE-775: Ленватиниб + Пембролизумаб в лечении распространённого эндометриального рака
Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm
Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
KEYNOTE-564 study
KEYNOTE-564 study
Oral Abstract Presentations | Kidney Cancer Research Summit 2025
Oral Abstract Presentations | Kidney Cancer Research Summit 2025
Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC
Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC